April 1, 2008 — Satoris, Inc., a molecular diagnostics company focused on developing blood-based tests for Alzheimer's disease, will shortly begin a collaborative study with the Mayo Foundation for Medical Education and Research (Mayo Clinic) to validate the utility of plasma biomarkers for earl detection of mild to moderate Alzheimer's disease. These biomarkers may also predict the progression of patients from a state of mild cognitive impairment to Alzheimer's. Satoris researchers first reported the utility of Alzheimer's�related biomarkers in the November, 2007 edition of the peer-reviewed scientific journal, Nature Medicine. In the reported study, researchers analyzed 259 stored blood samples, comparing those from individuals with presymptomatic to late-stage Alzheimer's disease with those from individuals without the disease... Satoris' Press Release -
Friday, April 11, 2008
Satoris : Collaboration to Validate Early Alzheimer's Test
April 1, 2008 — Satoris, Inc., a molecular diagnostics company focused on developing blood-based tests for Alzheimer's disease, will shortly begin a collaborative study with the Mayo Foundation for Medical Education and Research (Mayo Clinic) to validate the utility of plasma biomarkers for earl detection of mild to moderate Alzheimer's disease. These biomarkers may also predict the progression of patients from a state of mild cognitive impairment to Alzheimer's. Satoris researchers first reported the utility of Alzheimer's�related biomarkers in the November, 2007 edition of the peer-reviewed scientific journal, Nature Medicine. In the reported study, researchers analyzed 259 stored blood samples, comparing those from individuals with presymptomatic to late-stage Alzheimer's disease with those from individuals without the disease... Satoris' Press Release -
